Hesai Group (NASDAQ: HSAI; HKEX: 2525) delivered two headlines today: a return to profitability on record quarterly results and a fresh commercial win as the exclusive lidar supplier for Li Auto’s next‑generation assisted‑driving platform. Management also guided to double‑digit growth for Q4, underscoring momentum in both ADAS and robotics lidar shipments. [1]
Key takeaways
- Q3 2025 results: Net revenue RMB 795.4 million (+47.5% YoY), 441,398 lidar units shipped, gross margin 42.1%, and net income RMB 256.2 million (vs. loss a year ago). [2]
- New design win: Hesai chosen by Li Auto as exclusive lidar supplier across the L Series, i Series and MEGA model families for its next‑gen platform; Li Auto has delivered 1.46 million+ vehicles cumulatively and standardized lidar across new models since May 2025. [3]
- Outlook: Q4 2025 revenue guidance RMB 1.0–1.2 billion (+39% to +67% YoY). [4]
- Full‑year trajectory: Company says it hit its 2025 profit target one quarter early and raised full‑year GAAP net income guidance to RMB 350–450 million. [5]
By the numbers: Hesai’s record quarter
Hesai reported RMB 795.4 million in Q3 net revenue, up 47.5% year on year, and shipped 441,398 lidar sensors, including 380,759 for ADAS and 60,639 for robotics. Gross margin came in at 42.1%, while net income reached RMB 256.2 million, marking a clear swing back to profitability versus Q3 2024. Management highlighted a strengthened balance sheet with RMB 7.37 billion in cash, restricted cash and short‑term investments as of Sept. 30, 2025, supported by its recent Hong Kong listing. [6]
Strategic win with Li Auto
In a separate announcement, Hesai said Li Auto selected it as the exclusive lidar supplier for all models in the automaker’s next‑generation assisted‑driving platform—covering the L, i, and MEGA lines. Li Auto’s cumulative deliveries topped 1.46 million vehicles as of Oct. 31, and lidar has been standard on all new Li Auto models since May 2025—a strong demand signal for Hesai’s AT‑series sensors. The parties have collaborated since 2021 on automotive‑grade lidar development and mass production. [7]
Guidance and 2025 scorecard
For Q4 2025, Hesai guides revenue to RMB 1.0–1.2 billion, implying 39%–67% year‑over‑year growth. Management also said the company met its 2025 profit target a quarter ahead of plan and raised full‑year GAAP net income guidance to RMB 350–450 million—helped by shipment scale‑up, design‑win conversions and contribution from ADAS programs ramping into 2026. [8]
Why this matters
- ADAS is normalizing lidar. Li Auto’s move to make lidar standard across new models since May 2025, plus today’s platform‑wide award, reinforces lidar’s role in safety‑critical perception and redundancy—particularly as Chinese OEMs scale Level‑2+/Level‑3 features. [9]
- Scale begets margins. The combination of record shipments and positive GAAP earnings shows the operating model can leverage volume, even as product mix and program timing pressure gross margin near‑term. [10]
- Backlog & design‑win conversion. Management points to design wins across top ADAS customers slated for 100% adoption in 2026 model years, suggesting visibility into multi‑lidar architectures and rising per‑vehicle content. [11]
What to watch next
- Q4 delivery vs. guide: Can Hesai land within the RMB 1.0–1.2B range as ADAS programs scale and robotics demand holds? [12]
- Li Auto ramp details: Timing of next‑gen platform SOPs, per‑car lidar counts, and potential international models—all drivers of Hesai’s unit economics. [13]
- Margins & mix: Trajectory of gross margin as one‑time engineering revenue normalizes and higher‑volume SKUs dominate. (Management flagged both moving parts in today’s release.) [14]
- Regulatory backdrop: Hesai continues to navigate U.S. scrutiny; court actions around the Pentagon list and related appeals remain a background risk for investor sentiment. [15]
Earnings call
Hesai’s earnings conference call is scheduled for 7:00 a.m. U.S. Eastern Time on Tuesday, Nov. 11, 2025 (8:00 p.m. Beijing/Hong Kong). A live webcast and replay details are available via the company’s investor relations site (see release). [16]
Full context and source notes
- Q3 2025 earnings press release (figures, cash position, call details): Hesai reported RMB 795.4M revenue, RMB 256.2M net income, 441,398 lidar units; provided balance‑sheet and non‑GAAP reconciliations, plus Q4 outlook. [17]
- Li Auto award (exclusive supplier across platform): Official announcement confirms exclusive status and coverage of L/i/MEGA models; notes 1.46M cumulative deliveries and lidar standardization since May 2025. [18]
- Q4 2025 revenue guidance (range and YoY math): MarketScreener bulletin based on S&P Capital IQ reproduces RMB 1.0–1.2B range and YoY growth 39%–67%. [19]
- “Profit target hit one quarter early” and raised FY guidance: Independent recap confirms FY GAAP net income guidance raised to RMB 350–450M and notes Q3 profit record. [20]
- Secondary summaries / cross‑checks of the release: StockTItan mirrors key metrics and guidance commentary. [21]
Disclosure: This article is for information purposes only and is not investment advice. Always do your own research.
References
1. www.quiverquant.com, 2. www.quiverquant.com, 3. www.prnewswire.com, 4. www.marketscreener.com, 5. thebambooworks.com, 6. www.quiverquant.com, 7. www.prnewswire.com, 8. www.marketscreener.com, 9. www.prnewswire.com, 10. www.quiverquant.com, 11. www.quiverquant.com, 12. www.marketscreener.com, 13. www.prnewswire.com, 14. www.quiverquant.com, 15. www.reuters.com, 16. www.quiverquant.com, 17. www.quiverquant.com, 18. www.prnewswire.com, 19. www.marketscreener.com, 20. thebambooworks.com, 21. www.stocktitan.net

![Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025] Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]](https://ts2.tech/wp-content/uploads/2025/11/Quoin-Pharmaceuticals-1024x683.jpg)
